2 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2037. from the record
Of the 8 now held by other companies, 3 were conveyed to Genentech Inc. in the filing they arrived in, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2037
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2037 · High confidence
Also notable
Ends Nov 2042 · Medium confidence
Use of Tumor Dissociation Reagent in Flow Cytometry
US 11,644,405
Granted 2023. Computed term ends 2037.
Macrocyclic Compounds and Compositions, and Methods of Preparing and Using the Same
US 12,018,011
Granted 2024. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends Nov 2035 · High confidence
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2035.
conveyed to Genentech, Inc.
Also notable
Ends Mar 2030 · High confidence
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
now held by Merck Sharp & Dohme LLC
Also notable
Ends May 2037 · Medium confidence
The newest of the three, granted 2020. It anchors the portfolio to 2037, later than anything else here.
conveyed to Genentech Inc. - now held by Constellation Pharmaceuticals, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 term has ended since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Macrocyclic Compounds and Compositions, and Methods of Preparing and Using the Same | 1 in force | to Nov 2042 |
| Use of Tumor Dissociation Reagent in Flow Cytometry | 1 in force | to Aug 2037 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,644,405 | Use of Tumor Dissociation Reagent in Flow Cytometry held by Wuxi Apptec (Suzhou) Co. Ltd. In force · High confidence | In force | High confidence | |
| US 12,018,011 | Macrocyclic Compounds and Compositions, and Methods of Preparing and Using the Same held by Kura Oncology, Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 8 patents in force now held by others · 4 patents ended · 2 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed